Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer
- Univ. of Mexico School of Medicine, Albuquerque, NM (United States)
- Univ. of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Arrowhead Research Corp., Pasadena, CA (United States)
- Harvard Medical School, Boston, MA (United States)
Lung cancer is often refractory to radiotherapy, but molecular mechanisms of tumor resistance remain poorly defined. Here we show that the receptor tyrosine kinase EphA5 is specifically overexpressed in lung cancer and is involved in regulating cellular responses to genotoxic insult. In the absence of EphA5, lung cancer cells displayed a defective G1/S cell cycle checkpoint, were unable to resolve DNA damage, and became radiosensitive. Upon irradiation, EphA5 was transported into the nucleus where it interacted with activated ATM (ataxia-telangiectasia mutated) at sites of DNA repair. In conclusion, we demonstrate that a new monoclonal antibody against human EphA5 sensitized lung cancer cells and human lung cancer xenografts to radiotherapy and significantly prolonged survival, thus suggesting the likelihood of translational applications.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE
- Grant/Contract Number:
- AC52-06NA25396
- OSTI ID:
- 1225738
- Report Number(s):
- LA-UR-14-27894
- Journal Information:
- Journal of Biological Chemistry, Vol. 290, Issue 12; ISSN 0021-9258
- Publisher:
- American Society for Biochemistry and Molecular BiologyCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Similar Records
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Attenuation of the DNA Damage Response by Transforming Growth Factor-Beta Inhibitors Enhances Radiation Sensitivity of Non–Small-Cell Lung Cancer Cells In Vitro and In Vivo